This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early PD. N Engl J Med 321: 1364–1371
Palhagen S et al. (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66: 1200–1206
Rascol O et al. (2002) A 2-year multicenter, placebo-controlled, double-blind, parallel-group study of the effect of riluzole on Parkinson's disease progression. Mov Disord 17 (Suppl 5): S39
Shults CW et al. (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59: 1541–1550
Olanow CW et al. (2006) TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 5: 1013–1020
Shoulson I et al. (2006) CEP-1347 treatment fails to favorably modify the progression of Parkinson's disease (PRECEPT) study [abstract #S61.003]. Neurology 67: a185
Parkinson Study Group (2004) A controlled, randomized, delayed-start study of Rasagiline in early Parkinson disease. Arch Neurol 61: 561–566
Ravina B et al. (2005) The role of radiotracer imaging in Parkinson disease. Neurology 64: 208–215
9 NINDS NET-PD Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66: 664–671
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Karl Kieburtz has declared associations (support for research and/or consulting) with the following companies and organizations: Astellas Pharma US, Biogen Idec, Boehringer Ingelheim, Cephalon, the FDA, Medivation, Merz Pharmaceuticals, National Institutes of Health, Novartis Pharmaceuticals, Ortho-McNeil Neurologics, Prestwick Pharmaceuticals, Teva Pharmaceuticals and Vernalis.
Bernard Ravina has declared associations (support for research and/or consulting) with the following companies and organizations: Acadia, EnVivo, National Institutes of Health, Novartis, US Department of Defense, and Vernalis.
Rights and permissions
About this article
Cite this article
Kieburtz, K., Ravina, B. Why hasn't neuroprotection worked in Parkinson's disease?. Nat Rev Neurol 3, 240–241 (2007). https://doi.org/10.1038/ncpneuro0491
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0491